| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/02/2007 | US7157469 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis |
| 01/02/2007 | US7157457 Compounds useful in the treatment of inflammatory diseases |
| 01/02/2007 | US7157456 Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer |
| 01/02/2007 | US7157454 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 01/02/2007 | US7157451 Cardiac arrhythmias; potassium channel function inhibitors; such as 7-(3,4-Dichlorophenyl)-6-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-4,7 -dihydro-5-(methoxymethyl)pyrazolo-(1,5-a)pyrimidine |
| 01/02/2007 | US7157423 Using fumaric acid mono- and diamides, or monoamido fumaric acid monoesters for therapy of an autoimmune disease; transplantation medicine; therapy of mitochondrial diseases, for therapy of NF-kappaB mediated diseases |
| 01/02/2007 | US7157420 Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| 01/02/2007 | US7157250 Glutamic acid receptor and utilization thereof |
| 01/02/2007 | US7157248 Anticonvulsants; anxiolytic agents; multiple sclerosis; isolated nucleic acids; analyzing sample; calibration |
| 01/02/2007 | US7157243 DNA encoding mammalian T-type calcium channels |
| 01/02/2007 | US7157241 Dipeptidyl peptidase IV (DPPIV); given sequences; homology with family of prolyl oligopeptidases; drug screening for enzyme inhibitors for DPPIV which could treat reproductive, inflammatory and metabolic disorders |
| 01/02/2007 | US7157240 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 01/02/2007 | CA2400578C Controlled-release compositions containing opioid agonist and antagonist |
| 01/02/2007 | CA2371550C Ziprasidone suspension |
| 01/02/2007 | CA2283408C Swallow tablet comprising paracetamol |
| 01/02/2007 | CA2283255C Use of r-nsaid's for the prevention of alzheimer's disease |
| 01/02/2007 | CA2274464C Ketobenzamides as calpain inhibitors |
| 01/02/2007 | CA2236691C Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| 01/02/2007 | CA2211839C Use of melatonin for treating patients suffering from drug addiction |
| 01/02/2007 | CA2177602C N-substituted azabicycloalkane derivatives, their preparation and use |
| 01/02/2007 | CA2135709C Melatonin derivatives for use in treating sleep disorders |
| 12/30/2006 | CA2511200A1 Methods for increasing learning and memory in amyloid-beta-related neurodegenerative disorders by increasing uch-l1 activity and methods for identifying enhancers of uch-l1 activity |
| 12/28/2006 | WO2006138695A1 Triazolopyridine derivatives as cannabinoid receptor 1 antagonists |
| 12/28/2006 | WO2006138657A1 Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| 12/28/2006 | WO2006138604A1 Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders |
| 12/28/2006 | WO2006138549A1 Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists |
| 12/28/2006 | WO2006138510A1 Substituted enaminones as nicotinic acetylcholine receptor modulators |
| 12/28/2006 | WO2006138418A2 Improvement of cognitive performance with sirtuin activators |
| 12/28/2006 | WO2006138264A2 Aspartyl protease inhibitors |
| 12/28/2006 | WO2006138195A1 Macrocyclic heterocyclic aspartyl protease inhibitors |
| 12/28/2006 | WO2006138192A1 Aspartyl protease inhibitors |
| 12/28/2006 | WO2006138127A2 Botulinum toxin and the treatment of primary disorders of mood and affect |
| 12/28/2006 | WO2006138038A1 Intralesional treatment of psoriasis |
| 12/28/2006 | WO2006137797A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
| 12/28/2006 | WO2006137796A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
| 12/28/2006 | WO2006137795A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors useful for the treatment of hyperlipidaemic conditions |
| 12/28/2006 | WO2006137794A1 New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases |
| 12/28/2006 | WO2006137793A1 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
| 12/28/2006 | WO2006137792A1 New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions |
| 12/28/2006 | WO2006137791A1 New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases |
| 12/28/2006 | WO2006137790A1 New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases |
| 12/28/2006 | WO2006137789A1 Quinoline 3 -sulfonate esters as NK3 receptor modulators |
| 12/28/2006 | WO2006137527A1 Thiazole derivative |
| 12/28/2006 | WO2006137509A1 Cyclic amine derivative containing ppar regulator |
| 12/28/2006 | WO2006137469A1 Metabotropic glutamate receptor activator |
| 12/28/2006 | WO2006137465A1 Nitrogenated heterocyclic derivative |
| 12/28/2006 | WO2006137450A1 Crystal of phenylalanine derivative, process for producing the same and use thereof |
| 12/28/2006 | WO2006137443A1 Tablet containing hardly soluble active ingredient |
| 12/28/2006 | WO2006137421A1 Agent for topical administration |
| 12/28/2006 | WO2006137377A1 Neuronal regeneration promoter |
| 12/28/2006 | WO2006137354A1 Antibody having inhibitory effect on amyloid fibril formation |
| 12/28/2006 | WO2006137350A1 Novel furopyridine derivative, pharmaceutical composition comprising the derivative, and use of the derivative or composition |
| 12/28/2006 | WO2006137314A1 Radial brush |
| 12/28/2006 | WO2006136945A1 METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS |
| 12/28/2006 | WO2006136927A1 Extended release formulations comprising venlafaxine |
| 12/28/2006 | WO2006136841A1 Multiple sclerosis therapy and diagnosis |
| 12/28/2006 | WO2006136530A1 Halogenated pyrazolo [1,5-a]pyrimidines, processes, uses as gaba-a receptors ligand, compositions and intermediates |
| 12/28/2006 | WO2006136454A2 Use of inhibitors of n-methyl transferases for the therapy of parkinson's disease |
| 12/28/2006 | WO2006136442A1 Pyrimidine derivatives for the treatment op gaba b mediated nervous system disorders |
| 12/28/2006 | WO2006136305A1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM |
| 12/28/2006 | WO2006136304A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them |
| 12/28/2006 | WO2006136302A1 Solid pharmaceutical preparation containing (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman |
| 12/28/2006 | WO2006136245A1 Substituted spiro-compounds and the use thereof for producing medicaments |
| 12/28/2006 | WO2006136223A1 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
| 12/28/2006 | WO2006136114A1 Amniotic cells and methods for use thereof |
| 12/28/2006 | WO2006136006A1 Lgi, lingo and p75ntr family members: novel modulators of neuronal growth |
| 12/28/2006 | WO2006117461A3 Alkyl-, alkenyl- et alkynyl carbamate derivatives, the preparation and therapeutic use thereof |
| 12/28/2006 | WO2006099480A3 Stress proteins and peptides and methods of use thereof |
| 12/28/2006 | WO2006092032B1 PHARMACEUTICAL COMPOSITIONS CONTAINING 1-METHYL-3,6,7,8-TETRAHYDROPIRAZOLO[3,4-b]PIRROLO[4,3-d]PYRIDINE-6,8-DIONE DERIVATIVES, USE, AND PROCESS FOR PREPARING THEM |
| 12/28/2006 | WO2006089973A3 Dosage form containing oxycodone and naloxone |
| 12/28/2006 | WO2006082409A8 Tricyclic cytoprotective compounds |
| 12/28/2006 | WO2006081252A3 Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics |
| 12/28/2006 | WO2006076568A3 Thiazolopyridines as cannabinoid receptor modulators |
| 12/28/2006 | WO2006056873A3 Therapeutic pyrazolo[3,4-b] pyridines and indazoles |
| 12/28/2006 | WO2005087752A8 Substituted hydroxyethylamine aspartyl protease inhibitors |
| 12/28/2006 | WO2004041067A3 Prevention and treatment of synucleinopathic disease |
| 12/28/2006 | US20060293507 Crystallization of IGF-1 |
| 12/28/2006 | US20060293383 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 12/28/2006 | US20060293373 Gamma-secretase inhibitors |
| 12/28/2006 | US20060293360 4-(2-Phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| 12/28/2006 | US20060293348 CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis; 8-(2,4,6-trifluorophenyl)-4-(2,4-difluorophenyl)-2-(2-hydroxy-1-hydroxymethylethylamino)-8H-pyridio[2,3]pyrimidin-7-one |
| 12/28/2006 | US20060293347 Pharmaceutically active compounds |
| 12/28/2006 | US20060293332 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists |
| 12/28/2006 | US20060293326 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases |
| 12/28/2006 | US20060293313 Indole-3-alkyl-N-piperazine ring substituted with quinoline ring or derivatives; shows high affinity for both the dopamine D2 receptor and the serotonin reuptake site, useful for treating central nervous system disorders, such as anxiety disorders, depression, Parkinson's disease, and schizophrenia |
| 12/28/2006 | US20060293302 For therapy of acute inflammatory diseases: Septic shock, sepsis, SIRS, hemorrhagic shock, shock states induced by cytokine therapy (IL-2, TNF), organ transplantation and transplant rejection, head trauma, acute lung injury, ARDS, inflammatory skin conditions such as sunburn, inflammatory eye conditions |
| 12/28/2006 | US20060293299 3-((1S)-1-{1-[(S)-(3-cyanophenyl)(4-cyanophenyl)methyl]azetidin-3-yl}-2-fluoro-2-methylpropyl)-5-fluorobenzonitrile and its salts; antagonists and inverse agonists of the Cannabinoid-1 receptor |
| 12/28/2006 | US20060293289 Moderator of neurotransmitters releasing; analgesics ; central nervous system disorders; using N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine |
| 12/28/2006 | US20060293282 Substituted aminoalkanephosphonic acids |
| 12/28/2006 | US20060293275 Hgf production accelerator containing heparin-like oligosaccharide |
| 12/28/2006 | US20060293252 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics |
| 12/28/2006 | US20060293219 Methods of treating diabetes mellitus |
| 12/28/2006 | US20060292673 For degradation of glycosaminoglycans; inhibiting angiogenesis and cellular proliferation; treating cancer, neurodegenerative disease, atherosclerosis and microbial infection |
| 12/28/2006 | US20060292655 2-O sulfatase compositions and methods of analyzing therewith |
| 12/28/2006 | US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases |
| 12/28/2006 | US20060292622 determining the presence of or predisposition to early-onset spinocerebellar ataxia with ocular motor aprataxia and hypoalbuminemia in a human; neurodegenerative disease |
| 12/28/2006 | US20060292548 Using channel protein and immobilized nerve to identify inhibitors of bitter and/or sweet taste preception |
| 12/28/2006 | US20060292131 Chondrocyte Therapeutic Delivery System |
| 12/28/2006 | US20060292130 2-O sulfatase nucleic acid compositions |
| 12/28/2006 | US20060292128 Methods of treating schizophrenia |